The SCOUT Trial Explained: Reductil and Heart Risk

Few clinical trials have changed the fate of a drug as sharply as SCOUT changed the fate of sibutramine, sold as Reductil in Europe and as Meridia in North America. Within months of its results becoming public, the drug disappeared from pharmacies in the major regulated markets.

But headlines about “a heart risk trial” rarely explain what was actually done, who took part, or how big the risk really was. This article walks through the study step by step, translates the statistics into plain language, and looks fairly at the criticisms. If you want the wider regulatory story, read our companion piece, why was Reductil withdrawn from the market?. This post focuses on the evidence itself.

It is educational and does not replace advice from a healthcare professional.

Why SCOUT existed at all

Sibutramine worked by raising the activity of two brain chemicals, serotonin and noradrenaline. That helped reduce appetite, but noradrenaline also nudges heart rate and blood pressure upward. In the early 2000s, reports of cardiovascular problems in some users led European regulators to review the drug. The review did not remove it. Instead, it allowed the drug to stay on the market on one condition: the manufacturer had to run a large trial that could show, definitively, whether the drug was safe for the heart over the long term.

SCOUT, short for Sibutramine Cardiovascular Outcomes, was that trial. It began around 2002, ran for several years, and was funded by the manufacturer. The full results were published in the New England Journal of Medicine in 2010.

This design history matters for one reason. SCOUT was not an academic curiosity. It was a regulatory test, set up to answer a specific safety question, in a population chosen to reveal cardiovascular harm if it existed.

Reading the study, part 1: who took part

A study can only speak for people who resemble those it enrolled, so the first question is always “who was in it?”

The inclusion criteria

• Age 55 years or older
• Overweight or obese, with a body mass index in roughly the 27 to 45 range
• Either established cardiovascular disease (such as coronary artery disease, stroke, or peripheral arterial disease), or type 2 diabetes with at least one additional cardiovascular risk factor (such as high blood pressure, abnormal cholesterol, smoking, or kidney involvement), or both

Who was left out

People with very high or poorly controlled blood pressure, serious heart rhythm problems, severe heart failure, and certain other conditions were excluded. That is a standard safety step, but it also means the study did not include the very sickest patients.

The numbers

More than 10,000 people entered the first phase of the study. After a lead-in period, 9,804 were randomly assigned to treatment. The average follow-up in the randomised phase was a little over three years.

The key point about the population

This was deliberately a high-risk group. Most participants already had heart or blood vessel disease, or diabetes with extra risk factors. That is exactly the group in which any added cardiovascular risk would show up fastest, and it is also the group the drug’s labeling already warned against using it in. Hold on to this fact, because it is central to the debate we cover later.

Reading the study, part 2: how it was run

Step 1: the lead-in

Everyone first received sibutramine, together with a weight management programme of diet, activity, and behavioural advice, for about six weeks. This phase served as a filter. People who could not tolerate the drug, who had a worrying rise in blood pressure or pulse, or who did not lose any weight were not randomised.

Step 2: randomisation

Those who passed the lead-in were randomly assigned to either continue sibutramine (typically 10 mg once a day, with a possible increase to 15 mg) or switch to a matching placebo. Neither the participants nor the doctors knew who was taking what. This is called a double-blind design, and it reduces bias.

Step 3: the follow-up

Both groups continued with the same lifestyle support, so the main difference between them was the drug itself. Researchers then recorded events over time and had a committee review them.

Why the lead-in matters

This type of design is called an enriched design. By removing people who tolerated the drug badly, it tends to make the treatment look better than it would in everyday practice. In a safety study, that is important: if the drug still looked worse than placebo after this filter, then the real-world picture might be no better, and could be worse.

Reading the study, part 3: what was measured

The primary outcome

Researchers measured a combined endpoint, meaning the first occurrence of any one of four events:

1. Non-fatal heart attack (myocardial infarction)
2. Non-fatal stroke
3. Resuscitation after cardiac arrest
4. Death from a cardiovascular cause

Combining events like this is common in heart trials, because each individual event is relatively rare. Pooling them gives the study enough statistical power to detect a difference.

The secondary outcomes

These included the separate components of the composite (for example, non-fatal heart attack on its own), death from any cause, and measures such as weight, blood pressure, and pulse.

Reading the study, part 4: the results

The main finding

The primary outcome occurred in about 11.4% of people on sibutramine and about 10.0% of people on placebo. The statistical measure of the difference, the hazard ratio, was about 1.16, with a confidence interval running from roughly 1.03 to 1.31. In plain terms, that means a relative increase of about 16% in risk, and the range of uncertainty did not include “no difference”.

The individual components

Outcome	Sibutramine	Placebo	What it suggests
Primary composite outcome	About 11.4%	About 10.0%	Higher with sibutramine
Non-fatal heart attack	About 4.1%	About 3.2%	Higher with sibutramine
Non-fatal stroke	About 2.6%	About 1.9%	Higher with sibutramine
Cardiovascular death	About 4.5%	About 4.7%	No meaningful difference
Death from any cause	About 8.4%	About 8.0%	No significant difference

The pattern is important. The excess risk showed up in non-fatal events, not in deaths. A non-fatal heart attack or stroke can still cause lasting damage, such as heart failure, disability, or loss of independence, so “non-fatal” is not the same as “harmless”.

The weight and blood pressure picture

Sibutramine did lower weight. During the lead-in, participants lost a few kilograms on average. After randomisation, the sibutramine group kept a modest advantage over placebo, on the order of a couple of kilograms. Pulse rate was slightly higher on the drug, and blood pressure fell a little less than in the placebo group. These are small shifts for any one person, but across thousands of people over several years they were consistent with the drug’s known mechanism.

How to read the statistics: a mini-guide

Relative risk versus absolute risk

A “16% higher risk” sounds large. But relative figures can mislead without the baseline. Here, the baseline risk in this high-risk group was about 10% over roughly three and a half years, and sibutramine pushed it to about 11.4%. The absolute difference is about 1.4 percentage points.

Another way to express this is the number needed to harm. A difference of 1.4 percentage points means that about 70 people would have to take the drug for this period for one extra event to occur. That is not a huge number in individual terms, but when millions of people take a drug, small absolute risks add up to many events. And when the benefit is small, even a small harm becomes hard to justify.

Hazard ratio

A hazard ratio compares how quickly events happen in two groups. A value of 1.0 means no difference. Above 1.0 means more events in the treatment group. A hazard ratio of 1.16 indicates that, at any given moment, the treated group was about 16% more likely to experience the first event.

Confidence interval

The confidence interval shows the range of plausible true values. If the entire range sits above 1.0, as it did for the primary outcome in SCOUT, the result is unlikely to be explained by chance alone. If it crosses 1.0, the result is considered inconclusive. For more on interpreting trial results, the Cochrane website offers accessible training material.

Composite outcomes

Because the primary result combines four events, it is worth looking at the parts. In SCOUT, two components (heart attack and stroke) drove the excess, while cardiovascular death did not differ. A skeptic might say that pooling can exaggerate a result, but here the individual pieces pointed the same way.

Intention-to-treat

The main analysis counted people according to the group they were assigned to, even if they stopped taking the drug. This approach protects against bias, but it can dilute differences if many people stop treatment. It means the true effect in people who stayed on the drug could be somewhat larger than the headline figures.

What did regulators and critics make of it?

The case from regulators

Regulators weighed three things: a statistically significant increase in non-fatal heart attack and stroke, a very modest weight benefit, and the fact that the lead-in design had already filtered out people who did poorly on the drug. Taken together, they concluded that the benefit-risk balance had become unfavourable. You can read the U.S. agency’s reasoning in its drug safety communication.

The case from critics of the decision

Some clinicians and the manufacturer raised several objections:

1. Wrong population. The label already told doctors not to use the drug in people with heart disease. SCOUT enrolled exactly those people, so the results might not apply to the lower-risk patients the drug was intended for.
2. A combined endpoint. The significant result relied on a composite, and deaths did not differ.
3. Possible differences in adherence and monitoring. In real-world practice, blood pressure checks might have identified problems earlier.

A fair assessment

These objections are reasonable points to raise, and they highlight a genuine limitation. SCOUT cannot prove how large the risk would have been in younger, healthier people with no heart disease. But the counter-argument is also strong. Without a trial showing safety in lower-risk groups, regulators could not assume it. The drug’s upside was small. And in practice, obesity, high blood pressure, and diabetes often go together, so the line between “high risk” and “low risk” is blurry and not always known to patient or doctor.

Analyses by subgroup suggested that the excess risk was concentrated in people with established cardiovascular disease, which fits the argument that the label’s warning was well founded. But SCOUT was not designed to prove that point, and subgroup findings should be treated cautiously.

What SCOUT can and cannot tell us

It can tell us	It cannot tell us
That long-term sibutramine use in high-risk adults increased non-fatal heart attack and stroke	The exact risk in young, healthy people with no cardiovascular risk factors
That the weight loss advantage over placebo was modest	Whether modest weight loss would have translated into fewer events had the drug been safer
That the drug did not reduce cardiovascular death in this group	How the drug behaves beyond roughly three to four years of use
That blood pressure and pulse effects were real, if small	Whether every person’s risk is raised equally. Individual responses vary.

The bigger lesson: surrogate outcomes versus real outcomes

Sibutramine did what it was designed to do: it lowered weight. For years, that was treated as good enough evidence of benefit. SCOUT is a reminder that weight is a surrogate outcome. The things patients actually care about are living longer, avoiding heart attacks and strokes, and staying independent.

The trial effectively asked, “Does losing a little weight on this drug improve heart outcomes?” The answer was no, and in fact outcomes were somewhat worse. This was one of the events that pushed regulators to expect more outcome-based evidence for obesity drugs. Since then, large cardiovascular safety trials have become standard for newer weight management medicines, and some have shown benefits rather than harm. We cover current options in safer approved alternatives to Reductil for weight loss today.

What SCOUT means if you used Reductil or Meridia

• If you stopped years ago: there is no evidence that you need special testing because of past use. Keep up with standard checks of blood pressure, cholesterol, and blood sugar.
• If you have heart disease risk factors: mention your past use to your doctor, so that your overall risk can be assessed in context.
• If you find any product online claiming to be sibutramine: do not use it. It is not a regulated supply, and the content may be unknown. See hidden sibutramine in herbal slimming pills for how contaminated products slip through.

For practical steps to look after your heart, see our guide to natural ways to lower blood pressure and our discussion of stimulant-type drugs and the heart in is Adderall bad for your heart?

Does SCOUT say anything about phentermine?

Not directly. SCOUT studied only sibutramine. Phentermine is a different drug with a different mechanism, and it is licensed only for short-term use. It also raises heart rate and blood pressure in some people and is not suitable for those with heart disease, as we explain in realistic weight loss on phentermine. It is wrong to assume the results of one drug automatically apply to another, and equally wrong to assume the absence of a similar trial means safety. For a side-by-side look at the two drugs, see Reductil vs phentermine.

How to evaluate a weight loss drug study yourself

You can apply the lessons of SCOUT to any new treatment you read about. A short checklist:

1. Who was studied? Do they resemble you in age, health, and risk factors?
2. How long did it last? Weight drugs are often meant to be long-term, so short trials leave questions.
3. What was measured? Weight alone, or real outcomes like heart attacks and diabetes?
4. What is the comparison? Placebo, another drug, or no treatment?
5. What are the absolute numbers? Beware of percentages without baselines.
6. Who paid for it? Industry funding is common and not automatically a problem, but independent confirmation adds confidence.
7. Has it been replicated or reviewed by regulators? A single study is rarely the final word.

Glossary

Term	Plain meaning
Randomised controlled trial	A study where chance decides who gets the drug and who gets a comparison, to reduce bias
Double-blind	Neither participants nor doctors know who is receiving which treatment
Placebo	An inactive look-alike used for comparison
Primary outcome	The main result a study was designed to measure
Composite outcome	Several events counted together as one measure
Hazard ratio	How the speed of events compares between groups. Above 1.0 means more events in the treated group
Confidence interval	The range in which the true effect likely lies
Enriched design	A design that first screens out people who tolerate a treatment poorly
Surrogate outcome	A stand-in measure, like weight, used instead of a real clinical outcome

Frequently asked questions

What was the SCOUT trial?

It was a large randomised, double-blind trial that tested whether long-term sibutramine treatment changed the risk of heart attack, stroke, and cardiovascular death in overweight and obese adults aged 55 and over who were already at high cardiovascular risk.

How many people were in SCOUT?

More than 10,000 people entered the initial lead-in period, and 9,804 were randomly assigned to sibutramine or placebo.

What did SCOUT find?

The combined rate of non-fatal heart attack, non-fatal stroke, resuscitated cardiac arrest, and cardiovascular death was about 11.4% with sibutramine versus about 10.0% with placebo, a relative increase of roughly 16%. The excess came from non-fatal heart attacks and strokes.

Did sibutramine increase deaths?

Not significantly. Deaths from cardiovascular causes and from all causes were similar in both groups. The concern was the increase in non-fatal heart attacks and strokes.

Was the trial unfair to sibutramine?

That is debated. It enrolled people for whom the label already advised against the drug, so it likely overstated the risk for lower-risk patients. But regulators judged that the modest benefit and the lack of safety data in lower-risk groups made the balance unfavourable. Both views contain truth.

How much weight did people lose?

Average weight loss was modest, with only a small advantage over placebo after randomisation. That small benefit is part of why the added cardiovascular risk could not be justified.

Who funded SCOUT?

The manufacturer funded the trial, which was run under regulatory oversight as a condition of continued marketing in Europe.

Can I read the original paper?

Yes. It was published in the New England Journal of Medicine in 2010 under the title “Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects.” The link is in the sources below.

Does SCOUT mean all weight loss drugs are dangerous to the heart?

No. Different drugs act differently. SCOUT is a reason to ask for outcome evidence and to discuss your heart health with a clinician, not a reason to rule out all medical weight management.

The bottom line

SCOUT did what it was designed to do. It asked a clear question about heart safety, tested it in a large high-risk group over several years, and found that sibutramine increased non-fatal heart attacks and strokes while delivering only modest weight loss. The population debate is legitimate, but it does not change the central point: a drug with a small benefit has very little room for added cardiovascular risk.

For patients and readers, the most useful takeaway is how to read this kind of evidence: look at who was studied, what was measured, and the absolute size of the effects. Apply the same questions to any weight loss product, and keep your clinician involved in decisions that touch your heart.

Medical disclaimer: this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.

Sources and further reading

• New England Journal of Medicine: Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects (SCOUT)
• U.S. FDA: Drug Safety Communication on Meridia (sibutramine)
• European Medicines Agency: search “sibutramine” for the 2010 review
• Cochrane: training resources on understanding clinical evidence